Trial Profile

An Extended Access Program (EAP) for Perampanel

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perampanel (Primary)
Indications Partial epilepsies; Tonic-clonic epilepsy
Focus Expanded access; Therapeutic Use
Sponsors Eisai Inc

Most Recent Events

04 Dec 2018 Results of post hoc analysis assessing primary generalized tonic-clonic (PGTC) seizures, presented at the 72nd Annual Meeting of the American Epilepsy Society.
27 Apr 2018 Results of post-hoc analysis from this open-label extension phase assessing the effect of common concomitant antiepileptic drugs during adjunctive treatment with Perampanel, presented at the 70th Annual Meeting of the American Academy of Neurology.
27 Apr 2018 Results of a post-hoc analysis from NCT00735397, NCT01618695, NCT01161524 and NCT02307578 studies, presented at the 70th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com